 | Sheppard, Mullin, Richter & Hampton LLP |
30 Rockefeller Plaza |
New York, New York 10112-0015 |
212.653.8700 main |
212.653.8701 fax |
www.sheppardmullin.com |
VIA EDGAR
June 27, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: | Dillon Hagius |
| Laura Crotty |
| Re: | Aridis Pharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed June 9, 2023 File No. 333-272128 |
Ladies and Gentlemen:
This letter sets forth the responses of Aridis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to the comments received from the Staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) concerning its Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-272128) filed with the Commission on June 9, 2023 (the “Registration Statement”).
References in the text of the responses herein to captions and page numbers refer to Amendment No. 2 to the Company’s Registration Statement on Form S-1 (the “Amended Registration Statement”), which is being filed herewith.
Amendment No. 1 to Registration Statement on Form S-1
Cover Page
1. Given that this is a best-efforts, no minimum, and self-underwritten offering in which you are not required to arrange for the purchase and sale of any specific number or dollar amount of shares and that you may not sell the entire amount of common stock and warrants being offered, please delete the reference to the total amount of proceeds you may receive from the offering in the header on the cover page. Additionally, when known, please revise the header to quantify the number of shares underlying the warrants and prefunded warrants.
RESPONSE:
The Company respectfully acknowledges the Staff’s comment and has deleted the reference to the total amount of proceeds in the header on the cover page and added in the number of shares underlying the warrants and prefunded warrants.
*****
If any additional supplemental information is required by the Staff or if you have any questions regarding the foregoing, please contact Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP at (212) 634-3067 with any questions or further comments regarding the responses to the Staff’s comments.
| Very truly yours, |
| |
| /s/ Jeffrey Fessler |
| |
| Sheppard, Mullin, Richter & Hampton LLP |
cc: | Vu Truong, Chief Executive Officer |